Kirin Holdings Company (2503) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
11 Nov, 2025Executive summary
Revenue for Q3 FY2025 rose 3.3% year-over-year to ¥1,756.1 billion, driven by the consolidation of FANCL and steady performance across core businesses, with normalized operating profit up 5.2% to ¥170.5 billion.
Profit attributable to owners surged 29.7% to ¥102.8 billion, reflecting higher operating profit and the absence of prior-year one-time losses from FANCL step acquisitions.
All major business segments contributed positively except Pharmaceuticals, which saw planned declines.
Foreign exchange headwinds reduced revenue by ¥26.1 billion and normalized operating profit by ¥4.9 billion.
No revision to the full-year earnings forecast, though temporary demand from a competitor's cyberattack and other unquantified factors present both upside and downside risks.
Financial highlights
Revenue increased by ¥56.4 billion (3.3%) year-over-year; normalized operating profit rose by ¥8.5 billion (5.2%).
Gross profit increased 6.8% to ¥831.9 billion; operating profit rose 17.5% to ¥144.8 billion.
EPS climbed 29.7% to ¥127; normalized EBITDA reached ¥249.2 billion, up 7.1%.
Gross debt/equity ratio increased to 0.84; PBR rose due to higher share price.
Free cash flow improved to ¥71.9 billion from a negative ¥80.9 billion year-over-year.
Outlook and guidance
Full-year 2025 revenue forecast is ¥2,440 billion (+4.3% year-over-year), with normalized operating profit projected at ¥212 billion (+0.5%).
Profit before tax expected to jump 64.6% to ¥230 billion; profit attributable to owners forecast at ¥176 billion (+105.1%), with EPS of ¥185.20.
Dividend forecast raised to ¥74 per share for FY2025.
Management aims to achieve targets despite downside risks to profit and EPS.
Temporary demand from a competitor's cyberattack is not yet quantifiable for full-year impact.
Latest events from Kirin Holdings Company
- Profit more than doubled, Health Science turned profitable, and major portfolio moves were made.2503
Q4 202513 Feb 2026 - Targets high single-digit EPS growth, ROIC ≥10%, and 3 trillion yen market cap by 2035.2503
Investor presentation13 Feb 2026 - Double-digit revenue and profit growth, but profit guidance trimmed on higher taxes.2503
Q2 202425 Jan 2026 - Revenue rose 3.7% YoY, but profit and EPS fell on restructuring and FX impacts.2503
Q2 20257 Aug 2025 - Revenue and operating profit rose, but net profit dropped on FANCL acquisition loss.2503
Q3 202413 Jun 2025 - Revenue and profit grew, but net income fell on FX and equity changes from FANCL buyout.2503
Q1 20256 Jun 2025 - FY2025 profit is set to rebound sharply, driven by Health Science and Alcoholic Beverages.2503
Q4 20245 Jun 2025